Isah A O, Rawlins M D, Bateman D N
Wolfson Unit of Clinical Pharmacology, University of Newcastle upon Tyne.
Age Ageing. 1992 Jan;21(1):27-31. doi: 10.1093/ageing/21.1.27.
The pharmacokinetics and effects of prochlorperazine (PCZ) have been studied in six healthy elderly female volunteers in a double-blind placebo-controlled study of 3.125 mg intravenous (IV) and 25 mg oral PCZ. The pharmacokinetics of IV PCZ in elderly subjects appear similar to those previously obtained in young subjects, with a terminal half-life of 7.5 +/- 1.8 h after intravenous dosing. Oral bioavailability was low (14.7 +/- 1.5%). The pharmacological actions of prochlorperazine in elderly people appear to include antidopaminergic (prolactin rise) and anticholinergic (reduced salivary flow) effects. At the dose of PCZ used in this study, no significant haemodynamic or psychomotor changes were observed though there was a trend to prolongation of the movement component of the reaction time.
在一项双盲、安慰剂对照研究中，对6名健康老年女性志愿者进行了静脉注射3.125毫克和口服25毫克氯丙嗪（PCZ）的研究，以探讨其药代动力学及效应。老年受试者静脉注射PCZ的药代动力学与之前在年轻受试者中获得的结果相似，静脉给药后终末半衰期为7.5±1.8小时。口服生物利用度较低（14.7±1.5%）。氯丙嗪在老年人中的药理作用似乎包括抗多巴胺能（催乳素升高）和抗胆碱能（唾液分泌减少）效应。在本研究使用的PCZ剂量下，未观察到明显的血流动力学或精神运动变化，尽管反应时间的运动成分有延长趋势。
